leadf
logo-loader
viewC4X Discovery Holdings PLC

C4X Discovery - Cancellation and Regrant of Existing Share Options

RNS Number : 5136U
C4X Discovery Holdings PLC
29 July 2020
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Cancellation and Regrant of Existing Share Options

 

29 July 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that it is to cancel and reissue a number of unexpired options to subscribe for its ordinary shares of 0.1p each ("Ordinary Shares") which have been held by various employees and the Directors of the Company since their grant between 2015 and 2018 (the "Regrant").

 

The Regrant brings the strike price of the share options into line with the current market price of the Company's shares and should now deliver a viable incentive and reward package to the employees and Directors of the Company.

 

The Regrant options have an exercise price of 16p, being the closing price of the Ordinary Shares on 28 July 2020. The options can be exercised at any time between 3 years and 10 years of them being granted.

 

The share option holdings by the Directors of C4X Discovery before and after the Regrant are summarised as follows:

 


Options before Regrant

 Options following Regrant


Expiry Date

08-Jun-15

08-Dec-15

23-Nov-16

01-Feb-17

15-May-18


28-Jul-20


Director

Strike Price pence per Share

£1.00

£0.77

£1.05

£0.91

£0.892

Total

£0.16

Total

Clive Dix

Chief Executive Officer

20,000

125,000

0

0

50,000

195,000

195,000

195,000

Brad Hoy

Chief Financial Officer

0

0

300,000

0

50,000

350,000

350,000

350,000

Craig Fox

Chief Scientific Officer

150,000

0


50,000

50,000

250,000

250,000

250,000










TOTAL OPTIONS OUTSTANDING

170,000

125,000

300,000

50,000

150,000

795,000

795,000

795,000

 

 

- Ends -

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

James Stearns (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.

 

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

 

For additional information please go to: www.c4xdiscovery.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCSEFFDUESSEIW

Quick facts: C4X Discovery Holdings PLC

Price: 17.5

Market: AIM
Market Cap: £20.86 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

C4X Discovery CEO welcomes start of Indivior trial and outlines new...

C4X Discovery PLC's (LON:C4XD) Chief Executive Clive Dix speaks to Proactive London about the start of clinical trials of a treatment for opioid dependence. The phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year. Dix...

on 25/8/20

5 min read